RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radio-pharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radio-pharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radio-labeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology. RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.
External link for Radiomedix, Inc.
9701 Richmond Avenue, Suite 222,
Houston, Texas 77042, US
19705 Aldine Westfield Rd
Humble, Texas 77338, US
Radiomedix, Inc. reposted this
Sanofi will join Big Pharma peers Novartis, Bristol Myers Squibb and Eli Lilly and Company in radioligands, striking a $110 million licensing deal with Radiomedix, Inc. and Orano Med to develop AlphaMedix for neuroendocrine tumors. https://hubs.li/Q02PHTBR0 #pharma #biospace
We are thrilled to announce a groundbreaking licensing agreement with Sanofi and Orano Med to advance next generation radioligand medicine for rare cancers. This collaboration marks a significant step forward in our mission to develop innovative treatments for patients in need. Orano Med Sanofi Ebrahim Delpassand, M.D. Izabela Tworowska
Please subscribe to our new YouTube channel!! ✨ https://lnkd.in/gve4C_rj
🎇Happy Fourth of July! our office will be closed on July 4th as we celebrate the 4th of July, we honor the birth of the United States of America—the day when the Declaration of Independence was adopted in 1776 Let us remember the sacrifices of those who fought for our liberty and reflect on the principles that unite us. Our offices will be closed today, but we’ll be back to serve you tomorrow, July 5th. Enjoy the fireworks, spend time with loved ones, and embrace the spirit of unity that defines our nation. #radiomedix #4thjuly #radiopharmaceuticals #Oranomed #radiotherapy #nucmed #nuclearmedicine🧪
RadioMedix will be attending this year’s SNMMI❗️ Join us at Booth #1617 to learn more about our vision of treating Cancer with alpha therapeutics and our state-of-the art manufacturing facility in Houston Texas❗️ #SNMMI #radiomedix #toronto #snmmi24 #radiopharmaceutical #radiotherapy #nucmed #nuclearmedicine🧪
📢 Exciting Milestone Achieved in Alphamedix Phase 2 Study! With our partner Radiomedix, Inc. , we're proud to announce that the last patient in the PRRT-naive cohort of our Alphamedix™ Phase 2 study has received the final dose of study therapy ! We look forward to reporting data on the study in 2024, which we believe will show that AlphaMedix™ will provide substantial benefit over currently approved therapies for patients with metastatic or inoperable SSTR-expressing neuroendocrine tumors. This marks a significant step forward in advancing the development of targeted alphatherapies with lead-212 ! 🚀 #OranoMed #RLT #Radiopharmaceuticals
We are excited to share that the Inc Magazine's upcoming issue will feature the life story of Dr. Ebrahim (Abe) S. Delpassand, the CEO of Radio Medix. In the interview, he will discuss his groundbreaking work in radiopharmaceuticals and the future of cancer care. We are excited to offer readers a glimpse into Dr. Delpassand’ s visionary approach. #RadioMedix #DrEbrahimDelpassand #PET #Cancer #NETcancerday #Nuclearmedicine #PSMA #PsmaPET https://lnkd.in/gDr2YFrJ